Novartis AG
NVSEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $52 | $47 | $52 | $53 |
| % Growth | 10.8% | -10% | -2% | – |
| Cost of Goods Sold | $13 | $12 | $15 | $16 |
| Gross Profit | $39 | $35 | $36 | $37 |
| % Margin | 75.2% | 74.2% | 70.1% | 70% |
| R&D Expenses | $10 | $11 | $10 | $10 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13 | $12 | $14 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $1 | -$0 | $0 |
| Operating Expenses | $24 | $25 | $27 | $25 |
| Operating Income | $15 | $10 | $9 | $12 |
| % Margin | 28.1% | 20.9% | 17.7% | 22.1% |
| Other Income/Exp. Net | -$1 | -$1 | $0 | $13 |
| Pre-Tax Income | $14 | $9 | $8 | $25 |
| Tax Expense | $2 | $1 | $1 | $2 |
| Net Income | $12 | $15 | $7 | $24 |
| % Margin | 23.1% | 31.8% | 13.4% | 45.4% |
| EPS | 5.92 | 7.63 | 3.29 | 10.73 |
| % Growth | -22.4% | 131.9% | -69.3% | – |
| EPS Diluted | 5.87 | 7.58 | 3.27 | 10.65 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $6 | $9 | $7 | $5 |
| EBITDA | $21 | $20 | $15 | $17 |
| % Margin | 40.1% | 41.8% | 29.3% | 32.5% |